Cargando…

18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor

BACKGROUND: Pancreatic neuroendocrine tumor (PNET) is a subgroup of neuroendocrine tumor (NET) that has unique biology and natural history. The histological classification has a major role in the management of this pathology, but in recent years Gallium 68 dotatate (68Ga-DOTA) scanning is at the cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Queiroz, Marcello Moro, Lopes, Carlos Diego Holanda, Salgues, Alessandra Corte Real, Barbosa, Felipe de Galiza, Abe, Emerson Shigueaki, Silveira, Thales Parenti, Machado, Marcel Cerqueira Cesar, Capareli, Fernanda Cunha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218101/ https://www.ncbi.nlm.nih.gov/pubmed/34181108 http://dx.doi.org/10.1186/s41824-021-00103-4

Ejemplares similares

Prevalence and Characteristics of Incidentalomas Discovered by Whole Body FDG PETCT
por: Pampaloni, Miguel Hernandez, et al.
Publicado: (2012)

Zosteriform cutaneous metastases from an occult primary malignancy of lung identified by whole-body FDG PETCT imaging
por: Subramanyam, Padma, et al.
Publicado: (2016)

Clinical Value of PET.CT Based on Big Data in Colorectal and Peritoneal Metastatic Cancer
por: Xiang, Lili, et al.
Publicado: (2022)

Application value of 18F-FDG PETCT imaging in the clinical initial diagnosis and follow-up of primary lesions of cervical cancer
por: Tan, Beibei, et al.
Publicado: (2020)

The relationship between (18)F-FDG-PETCT-derived tumour metabolic activity, nutritional risk, body composition, systemic inflammation and survival in patients with lung cancer
por: Dolan, Ross D., et al.
Publicado: (2020)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG Uptake in Esophageal Cancer
por: Liu, Huipan, et al.
Publicado: (2022)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/MRI in the Preoperative Diagnosis of Gastric Cancer
por: Du, Tao, et al.
Publicado: (2023)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma
por: Gu, Bingxin, et al.
Publicado: (2022)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

Role of Combined [(68)Ga]Ga-DOTA-SST Analogues and [(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
por: Carideo, Luciano, et al.
Publicado: (2019)

Assessment of regional pulmonary blood flow using (68)Ga-DOTA PET
por: Velasco, Carlos, et al.
Publicado: (2017)

A systematic review of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/CT in the diagnostic value of malignant tumor bone metastasis
por: Li, Lanying, et al.
Publicado: (2022)

Head-to-Head Comparison between [(68)Ga]Ga-DOTA.SA.FAPi and [(18)F]F-FDG PET/CT Imaging in Patients with Breast Cancer
por: Ballal, Sanjana, et al.
Publicado: (2023)

Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report
por: Nappo, Gennaro, et al.
Publicado: (2020)

Synthesis of a DOTA-C-glyco bifunctional chelating agent and preliminary in vitro and in vivo study of [(68)Ga]Ga-DOTA-C-glyco-RGD
por: Mangin, Floriane, et al.
Publicado: (2021)

Kinetic Modelling of [(68)Ga]Ga-DOTA-Siglec-9 in Porcine Osteomyelitis and Soft Tissue Infections
por: Jødal, Lars, et al.
Publicado: (2019)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

Comparison of the Relative Diagnostic Performance of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers
por: Wu, Junhao, et al.
Publicado: (2021)

(68)Ga-DOTA-Siglec-9 – a new imaging tool to detect synovitis
por: Virtanen, Helena, et al.
Publicado: (2015)

The role of (68)Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome
por: Ceccato, Filippo, et al.
Publicado: (2020)

Prevalence of Brain Incidental Lesions Detected by (68)Ga-DOTA Peptides PET/CT
por: Albano, Domenico, et al.
Publicado: (2022)

Preparation, biological characterization and preliminary human imaging studies of (68)Ga-DOTA-IBA
por: Wang, Yingwei, et al.
Publicado: (2022)

Diagnostic challenges in a patient with an occult insulinoma:(68 )Ga‐DOTA‐exendin‐4 PET/CT and (68)Ga‐DOTATATE PET/CT
por: Bongetti, Elisa, et al.
Publicado: (2018)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression
por: Migliari, Silvia, et al.
Publicado: (2023)

The utility of (18)F-FDG and (68)Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis
por: Jiang, Yuanyuan, et al.
Publicado: (2019)

Pilot study of (68)Ga-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer
por: Beylergil, Volkan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n58s2ej2r8e7qdu14pmp2odd3j